Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Medically reviewed by William Truswell, MD Psoriasis is a chronic skin condition with many options to help manage your ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

Biologics often help when other treatments haven’t worked to treat psoriasis. They’re synthetic versions of proteins created from human cells that target specific parts of your immune system.

As a group, these new medications are commonly referred to as "biologics" and represent the most current attempt to target specific steps in the immune mechanisms underlying psoriasis. It is the ...

Systemic biologics are better for cases of psoriasis that do not resolve with lower-potency topicals, so the patient can avoid applying high-potency drugs over large areas of the body.

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Based on these observations, many new biologic ... predominant in psoriasis; and 4) blockade of cytokine production. The goal of these new therapies is to improve the treatment of psoriasis ...

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...